The story of Octapharma began in the 1980s, when we pioneered the introduction of virally inactivated Factor VIII for the treatment of hemophilia patients. Since then, we have introduced several life saving or life enhancing treatments that have helped people lead normal lives. We have provided innovative solutions that include helping several countries meet their self-sufficiency goals for plasma products by fractionating their collected plasma.
Fractionation involves the extraction of highly specific proteins or factors that play a crucial part in the coagulation cascade to develop a series of therapeutically beneficial treatments. Each of these products is treated with solvent-detergent technology and other additional viral inactivation methods to ensure unmatched viral inactivation and product purity. The end result of this is an unsurpassed array of highly beneficial biopharmaceutical products.
These treatments are focused on improving outcomes for patients in three therapeutic areas:
- HematologyInherited bleeding disorders
- ImmunotherapyImmunological disorders
- Critical CareEmergency and peri-operative bleed management, large volume plasma exchange procedures
The demand for our state-of-the-art product introductions and constantly expanding manufacturing capabilities has strengthened our position as the world’s largest privately held plasma therapeutics company. Octapharma products and services are available in over 100 countries world wide, with a significant and direct presence in North America, Europe, Russia, Brazil, Australia, the Middle East and emerging economies. Our family includes over 4,500 direct employees and many other partners. We own and operate six state-of-the-art production facilities in Europe and North America and, in addition, we also own and operate over 70 plasma collection centres – making us a fully integrated manufacturer and supplier of plasma proteins.